These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 9164314

  • 1. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
    Lancet; 1997 May 17; 349(9063):1413-21. PubMed ID: 9164314
    [Abstract] [Full Text] [Related]

  • 2. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    Montaner JS, DeMasi R, Hill AM.
    AIDS; 1998 Mar 26; 12(5):F23-8. PubMed ID: 9543436
    [Abstract] [Full Text] [Related]

  • 3. Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection.
    Chatterton ML, Scott-Lennox J, Wu AW, Scott J.
    Pharmacoeconomics; 1999 Mar 26; 15 Suppl 1():67-74. PubMed ID: 10537443
    [Abstract] [Full Text] [Related]

  • 4. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K, Erice A, Tierney C, Balfour HH, Fischl MA, Kmack A, Liou SH, Kenton A, Hirsch MS, Phair J, Martinez A, Kahn JO.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec 01; 19(4):339-49. PubMed ID: 9833742
    [Abstract] [Full Text] [Related]

  • 5. AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group.
    Gatell J, Lange J, Gartland M.
    Antivir Ther; 1999 Dec 01; 4(2):79-86. PubMed ID: 10682152
    [Abstract] [Full Text] [Related]

  • 6. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct 01; 12(14):F151-60. PubMed ID: 9792371
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H.
    JAMA; 1996 Jul 10; 276(2):118-25. PubMed ID: 8656503
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhøj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H.
    JAMA; 1996 Jul 10; 276(2):111-7. PubMed ID: 8656502
    [Abstract] [Full Text] [Related]

  • 9. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA.
    N Engl J Med; 1997 Sep 11; 337(11):725-33. PubMed ID: 9287227
    [Abstract] [Full Text] [Related]

  • 10. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun 12; 353(9169):2014-25. PubMed ID: 10376616
    [Abstract] [Full Text] [Related]

  • 11. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 12. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM, ACTG 303 Study Team.
    AIDS Res Hum Retroviruses; 2000 Sep 20; 16(14):1337-44. PubMed ID: 11018853
    [Abstract] [Full Text] [Related]

  • 13. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
    Antivir Ther; 2002 Mar 20; 7(1):11-20. PubMed ID: 12008783
    [Abstract] [Full Text] [Related]

  • 14. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM, Chêne G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM.
    J Infect Dis; 1999 Aug 20; 180(2):351-8. PubMed ID: 10395849
    [Abstract] [Full Text] [Related]

  • 15. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Aug 20; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 16. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug 20; 10 Suppl 1():S57. PubMed ID: 8595510
    [Abstract] [Full Text] [Related]

  • 17. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M, AVANTI Study Group.
    Antivir Ther; 2001 Jun 20; 6(2):127-34. PubMed ID: 11491417
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.
    Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V.
    AIDS; 2008 Jan 11; 22(2):275-9. PubMed ID: 18097230
    [Abstract] [Full Text] [Related]

  • 19. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ, Bouza E, Antunes F, Smith D, Harris R, Warburg M, Walker M.
    Antivir Ther; 1997 Dec 11; 2(4):229-36. PubMed ID: 11327442
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, Greaves W, Fätkenheuer G.
    J Infect Dis; 2008 Oct 15; 198(8):1113-22. PubMed ID: 18783318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.